Matinas BioPharma Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Bedminster, State of New Jersey on March 31, 2026.
| MATINAS BIOPHARMA HOLDINGS, INC. | |
| By: | /s/ Jerome D. Jabbour |
| Name: | Jerome D. Jabbour |
| Title: | Chairman, Chief Executive Officer, President & Interim Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Person | Capacity | Date |
|---|---|---|
| /s/ Jerome D. Jabbour | Chairman, Chief Executive Officer, President & Interim Chief Financial Officer | March 31, 2026 |
| Jerome D. Jabbour | (Principal Executive Officer and Principal Financial and Accounting Officer) | |
| /s/ Evelyn D’An | Director | March 31, 2026 |
| Evelyn D’An | ||
| /s/ Keith Murphy | Director | March 31, 2026 |
| Keith Murphy | ||
| /s/ Edward Neugeboren | Director | March 31, 2026 |
| Edward Neugeboren | ||
| /s/ Robin L. Smith | Director | March 31, 2026 |
| Robin L. Smith | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.